Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease in more than a decade.

Increasingly, research is pointing to the reality that while vapes do not contain the same dangerous chemicals as cigarettes, ...

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with actionable improvement strategies.

Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.

Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe ...

Many individuals with chronic obstructive pulmonary disease describe exacerbations in personal, varied terms, revealing a ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...

Serious conditions behind bloody cough symptoms revealed. Life-threatening diseases that cause alarming blood in cough ...

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...